Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2022 Oct;15(10):e008942.
doi: 10.1161/CIRCOUTCOMES.122.008942. Epub 2022 Oct 4.

Relationship Between Preexisting Cardiovascular Disease and Death and Cardiovascular Outcomes in Critically Ill Patients With COVID-19

Alexi Vasbinder #  1 , Chelsea Meloche #  2 , Tariq U Azam #  2 , Elizabeth Anderson  1 , Tonimarie Catalan  1 , Husam Shadid  2 , Hanna Berlin  2 , Michael Pan  1 , Patrick O'Hayer  1 , Kishan Padalia  1 , Pennelope Blakely  1 , Ibrahim Khaleel  1 , Erinleigh Michaud  1 , Yiyuan Huang  3 , Lili Zhao  3 , Rodica Pop-Busui  4 , Shruti Gupta  5 , Kim Eagle #  1 , David E Leaf #  5 , Salim S Hayek #  1 ; STOP-COVID Investigators‡
Collaborators, Affiliations
Multicenter Study

Relationship Between Preexisting Cardiovascular Disease and Death and Cardiovascular Outcomes in Critically Ill Patients With COVID-19

Alexi Vasbinder et al. Circ Cardiovasc Qual Outcomes. 2022 Oct.

Abstract

Background: Preexisting cardiovascular disease (CVD) is perceived as a risk factor for poor outcomes in patients with COVID-19. We sought to determine whether CVD is associated with in-hospital death and cardiovascular events in critically ill patients with COVID-19.

Methods: This study used data from a multicenter cohort of adults with laboratory-confirmed COVID-19 admitted to intensive care units at 68 centers across the United States from March 1 to July 1, 2020. The primary exposure was CVD, defined as preexisting coronary artery disease, congestive heart failure, or atrial fibrillation/flutter. Myocardial injury on intensive care unit admission defined as a troponin I or T level above the 99th percentile upper reference limit of normal was a secondary exposure. The primary outcome was 28-day in-hospital mortality. Secondary outcomes included cardiovascular events (cardiac arrest, new-onset arrhythmias, new-onset heart failure, myocarditis, pericarditis, or stroke) within 14 days.

Results: Among 5133 patients (3231 male [62.9%]; mean age 61 years [SD, 15]), 1174 (22.9%) had preexisting CVD. A total of 1178 (34.6%) died, and 920 (17.9%) had a cardiovascular event. After adjusting for age, sex, race, body mass index, history of smoking, and comorbidities, preexisting CVD was associated with a 1.15 (95% CI, 0.98-1.34) higher odds of death. No independent association was observed between preexisting CVD and cardiovascular events. Myocardial injury on intensive care unit admission was associated with higher odds of death (adjusted odds ratio, 1.93 [95% CI, 1.61-2.31]) and cardiovascular events (adjusted odds ratio, 1.82 [95% CI, 1.47-2.24]), regardless of the presence of CVD.

Conclusions: CVD risk factors, rather than CVD itself, were the major contributors to outcomes in critically ill patients with COVID-19. The occurrence of myocardial injury, regardless of CVD, and its association with outcomes suggests it is likely due to multiorgan injury related to acute inflammation rather than exacerbation of preexisting CVD.

Registration: NCT04343898; https://clinicaltrials.gov/ct2/show/NCT04343898.

Keywords: COVID-19; cardiovascular disease; cardiovascular risk factors; inflammation; troponin.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Associations between cardiovascular disease, coronary artery disease, and congestive heart failure with 28-day mortality and cardiovascular events. Bar graphs depicting the odds ratio and 95% CIs for 28-day mortality (A) and cardiovascular events (B) using 4 different models. Model 0 was unadjusted. Model 1 was adjusted for age, race and ethnicity, and sex. Model 2 incorporated model 1 in addition to body mass index, smoking status, and history of preexisting diabetes, hypertension, and chronic kidney disease. Model 3 included the modified Sequential Organ Failure Assessment (SOFA) score. Based on model 3, neither cardiovascular disease, coronary artery disease nor congestive heart failure was associated with 28-day mortality.
Figure 2.
Figure 2.
Bar graphs comparing measures of COVID-19 illness severity by myocardial injury on admission for mechanical ventilation, modified Sequential Organ Failure Assessment (mSOFA) score, creatinine, and CRP (C-reactive protein). A, Proportion of patients on mechanical ventilation at intensive care unit (ICU) admission. B, C, and D, Compare the means of modified SOFA scores, creatinine, and CRP between patients with and without myocardial injury at ICU admission. Creatinine and CRP are log2 transformed.
Figure 3.
Figure 3.
Associations between troponin elevation on intensive care unit (ICU) admission and troponin fold change during hospitalization with 28-day mortality and cardiovascular events. Bar graphs depicting the odds ratios and 95% CIs for 28-day mortality (A) and cardiovascular events (B) based on acute cardiac injury on ICU admission categorized as troponin elevation 1–2x, 2–3x, 3–4x, and >4x the upper reference limit of normal vs no acute cardiac injury (reference) based on model 3. C and D, Odds ratios and 95% CIs based on the absolute fold change in troponin during hospitalization categorized as an absolute fold change of <1.29, 1.3%–9.3%, and >9.3% compared with patients with no elevated troponin measurements during hospitalization (reference) for 28-day mortality (C) and cardiovascular events (D) based on model 3.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. John Hopkins University Coronavirus Resource Center. COVID-19 United states cases by county by the Center for Systems Science and Engineering (CSSE) at Johns Hopskins Univeristy. Available at https://coronavirus.jhu.edu/us-map. Accessed July 14, 2022.
    1. Macedo A, Gonçalves N, Febra C. COVID-19 fatality rates in hospitalized patients: systematic review and meta-analysis. Ann Epidemiol. 2021;57:14–21. doi: 10.1016/j.annepidem.2021.02.012 - PMC - PubMed
    1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the chinese center for disease control and prevention. JAMA. 2020;323:1239–1242. doi: 10.1001/jama.2020.2648 - PubMed
    1. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324:782–793. doi: 10.1001/jama.2020.12839 - PubMed
    1. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, Barnaby DP, Becker LB, Chelico JD, Cohen SL, et al. ; the Northwell COVID-19 Research Consortium. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA. 2020;323:2052–2059. doi: 10.1001/jama.2020.6775 - PMC - PubMed

Publication types

Associated data